Skip to content
DraconiticResearch
Search Sources API
209,918 studies31 sourcesUpdated 3 min ago

Oncology

5,300 studies557 in 7 days2,546 in 30 days

Filters
Type
Date
Clear

Latest

5,300 studies

  1. Feasibility of a structured digital patient-reported assessment pathway in older adults with acute leukaemia in Spain: protocol for a prospective single-centre, single-arm pilot study
    Carmen Loredo Alvarez, Ainhoa Fernández Moreno, Mara Celis Alvarez +2
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textOncologyCrossrefEurope PMC
  2. Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial
    Ying Jin, Weishan Lu, Lishu Lou +3
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textOncologyCrossrefPMC
  3. A multi-omics study integrating single-cell transcriptomics, spatial transcriptomics, and mendelian randomization unveil the implication of TRDMT1 expression in T cells on the immunotherapeutic response and prognosis in breast cancer.
    Tingjun Li, Cheng Huang, Haolan Deng +6
    Functional & integrative genomicsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Cardiovascular biomarker phenotype associated with immune checkpoint inhibitor therapy in patients with non-small cell lung cancer: an exploratory blood transcriptome study
    Joanna Ziemska-Legięcka, Natalia Żeber-Lubecka, Magdalena Borucka +13
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Viruses in the tumor immune microenvironment: implications for immunotherapy
    Xuemin Chen, Ping Ni, Wei Li +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  6. Nanotechnology for next-generation CAR T-Cell manufacturing
    Mark Schvartzman, Saba Ghassemi
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  7. Immune checkpoint inhibitor-induced multi-organ immune damage complicated by severe pneumonia: case report
    Tingrui Zhao, Rongzhang Chen, Yuhua Ma +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  8. Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial
    Haiqi Lu, Xufei Wang, Zhuo Wang +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  9. Magnetic enrichment–coupled flow cytometry for highly sensitive detection of persistent CAR-T cells in spiked and clinical peripheral blood samples
    Loubna Abdel Hadi, Gokul Thangamani, Samira Sheikh +7
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  10. Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens
    Dana Dildabayeva, Diana Samarkhanova, Larissa Lezina
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0OncologyCrossref
  11. PLOD3 Variably Regulates Diverse Phenotypes in Human Cancer Cells
    Xiaoxiao Zhang, Mingmin Zhang, Xue Zhang +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0OncologyCrossref
  12. Global, Regional, and National Burden of Ovarian Cancer Among Women of Reproductive Age, 1990–2021, with Projections to 2040: A Global Burden of Disease Study 2021 Analysis
    Xiao-Long Yang, Su-Su Yang, Jia-Ming Hou +6
    International Journal of Women's HealthPeer-reviewedCC BY-NC 4.0Full textOncologyPMCEurope PMC
  13. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
    Khyati Meghani, Walker Fuchs, Alexandre Detappe +8
    Cell ReportsPeer-reviewedCC BY-NC-NDFull text71 citedOncologyHAL
  14. Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity
    Eva Tsaousidou, Jędrzej Chrzanowski, Pascal Drané +14
    Cell ReportsPeer-reviewedCC BY-NC-ND4 citedOncologyHAL
  15. TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs
    Nishita Parnandi, Veronica Rendo, Gaofeng Cui +8
    Molecular CellPeer-reviewedLicence not statedOncologyHAL
  16. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
    Nelson F Freeburg, Daniel Chafamo, Gayathri Konanur Gopikrishna +47
    CellPeer-reviewedCC BY 4.0Full text4 citedOncologyHAL
  17. Synthesis, spectroscopic study, antioxidant, DNA-cleavage and enzyme-mimicking activities for metal(II/III) complexes with azo ligand–eugenol scaffold
    Huda Muayad Nafea, Abbas Ali Salih Al-Hamdani
    Royal Society Open SciencePeer-reviewedCC BY 4.0Full text1 citedOncologyCrossrefEurope PMC
  18. CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer
    Qing Gao, Kehong Wei, Deshen Pan +6
    Science AdvancesPeer-reviewedCC BY-NCFull textOncologyCrossrefEurope PMC
  19. Molecular characterization of large cell neuroendocrine carcinoma of the lung by multilayered omics analysis
    Megumi Tateishi, Yoshiki Otsuka, Ryota Matsuoka +17
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  20. PARG inhibition elicits cytotoxicity by sequestering XRCC1 and other PAR-binding proteins into PAR-dependent nuclear condensates
    Isaac Dumoulin, Brian J. Lee, Chuhan Zhang +5
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  21. Quality of life and associated factors in patients three months after spinal tumor surgery
    Edyta Laska
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  22. Prognostic value of RDW-to-platelet ratio for short- and long-term mortality after cardiac surgery: dual-center MIMIC-IV and external validation
    Qiannan Guo, Yuehang Yang, Hanshen Luo +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  23. Platelet to white blood cell ratio and short term mortality in critically ill patients with HFpEF
    Zhantao Cao, Ziyi Chen, Yue Wei +4
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  24. The global burden of female breast cancer attributable to high fasting plasma glucose: A comprehensive analysis of the GBD database from 1990 to 2023
    Huadi Shi, Zhi Song, Yaoyao Chen +2
    PLOS OnePeer-reviewedCC BYFull textEndocrinology & metabolismEpidemiology & public healthOncologyPLOSEurope PMC
  25. Modifiable psychosocial risk factors for depression among cancer survivors in the United States
    Philip Baiden, Batholomew Chireh, Judith S Anagbonu
    PLOS OnePeer-reviewedCC BYFull textOncologyPsychiatry & mental healthPLOSEurope PMC